<DOC>
	<DOCNO>NCT00002035</DOCNO>
	<brief_summary>To compare efficacy safety orally administer didanosine ( ddI ) orally administer zidovudine ( AZT ) treatment patient exhibit increase clinical deterioration despite treatment AZT .</brief_summary>
	<brief_title>Double-Blind Comparison Efficacy Continued Zidovudine Versus 2',3'-Dideoxyinosine ( ddI ) ( BMY-40900 ) Treatment Patients With AIDS AIDS-Related Complex Increasing Symptomatology Despite Treatment With Zidovudine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed Hematologic toxicity : Erythropoietin . ColonyStimulating Factors . Allowed prophylaxis Pneumocystis carinii pneumonia ( PCP ) : Aerosolized pentamidine . Trimethoprim/sulfamethoxazole . Dapsone . NOTE : If intravenous pentamidine require treatment PCP , study drug suspend one week completion intravenous pentamidine . Allowed : Prophylactic suppressive therapy begin prior study entry exception neurotoxic agent ( define protocol ) . Concurrent Treatment : Allowed : Transfusions hematologic toxicity . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active acute AIDS defining infection . Clinical evidence acute pancreatitis last two year chronic pancreatitis . Dementia severity patient give inform consent . Grade 2 bad peripheral neuropathy define Targeted Neuropathy Score ( Schaumberg ) . Prior Cytomegalovirus disease require ongoing systemic ganciclovir therapy . Extensive Kaposi 's sarcoma malignancy require systemic cytotoxic myelosuppressive neurotoxic chemotherapy . Cardiomyopathy need antiarrhythmic therapy . Inability tolerate least 600 mg per day zidovudine ( AZT ) . Seizures within last 6 month need anticonvulsant therapy . Concurrent Medication : Excluded : Ganciclovir ( DHPG ) . Myelosuppressive neurotoxic chemotherapy . Antiarrhythmic therapy . Anticonvulsant therapy . Neurotoxic agent ( define protocol ) . NOTE : If intravenous pentamidine require treatment Pneumocystis carinii pneumonia ( PCP ) , study drug suspend 1 week completion intravenous pentamidine . Patients follow exclude : Symptoms condition define Patient Exclusion CoExisting Conditions field . Average two sequential CD4 count SciCor Clinical Laboratories 30 day prior study entry &gt; 300 cells/mm3 . Prior Medication : Excluded , participation study use : Dideoxyinosine ( ddI ) . 2',3'Dideoxy2',3'didehydrothymidine ( d4T ) . Dideoxycytidine ( ddC ) . Excluded within one month study entry : Any experimental antiretroviral compound . Patients must : Have document HIV positivity via ELISA . Meet CDC criterion AIDS AIDS relate complex ( ARC ) . Have receive zidovudine ( AZT ) = &gt; 6 month tolerate dose least 500 mg per day without significant hematologic toxicity . Have acute AIDS defining opportunistic infection , may receive suppressive therapy infection . Demonstrate least one follow criterion clinical deterioration despite AZT therapy within 4 week prior study entry ( 8 week prior weight loss ) : involuntary weight loss 5 percent body weight occur 8 week period prior study entry , Karnofsky score = &gt; 50 demonstrate fall = &gt; 20 previous level functioning ( assessment must persistent two occasion least 14 day apart ) , unexplained fever = &gt; 38 degree C ( despite evaluation define protocol ) 7 day , appearance newly diagnose oral hairy leukoplakia oral candidiasis , recurrence previously quiescent multidermatomal varicellazoster , appearance dermatologic affliction ( e.g . psoriasis , molluscum contagiosum , newly diagnose seborrheic dermatitis ) , appearance chronic herpetic ulcer responsive acyclovir therapy . Required : Zidovudine ( AZT ) = &gt; 6 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>